ALPS Medical Breakthrough

Mirum Pharmaceuticals Launches $600M Convertible Senior Note Private Placement

UBS Maintains Buy Rating on CG Oncology with $90 Target Price Based on Bladder Cancer Therapy Data

LifeSci Capital Analyst Slutsky Reaffirms Buy Rating on SYRE with $103 Price Target

CG Oncology Plans Q4 BLA Submission for Bladder Cancer Drug Cretostimogene

CG Oncology Announces 92.3% Complete Response Rate in Bladder Cancer Drug Trial

Celcuity released FY2026 Q1 earnings on May 14 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9702 (forecast USD -1.0636)

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Celcuity Inc. Expands Gedatolisib Phase III Trial and Receives FDA Priority Review Designation

Mirum Pharmaceuticals Issues $600 Million Convertible Senior Notes Offering

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Apogee Therapeutic released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0637 (forecast USD -1.0822)

CG Oncology released FY2026 Q1 earnings on May 8 (EST), actual revenue USD 1.083 M (forecast USD 453.03 K), actual EPS USD -0.7122 (forecast USD -0.5677)

Michael Thomas Henderson sold 80,000 shares of Spyre Therapeutics

Apellis Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 268.3 M (forecast USD 203.29 M), actual EPS USD 0.1461 (forecast USD -0.3526)

Newamsterdam Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 3.04 M (forecast USD 1.061 M), actual EPS USD -0.4 (forecast USD -0.4689)

Xenon Pharma released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 0 (forecast USD 1 M), actual EPS USD -1.1712 (forecast USD -1.1871)

Celcuity to Release FY2026 Q1 Earnings on May 14 After-Market EST, Forecast EPS USD -1.0636

Mirum Pharmaceuticals released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 159.88 M (forecast USD 153.05 M), actual EPS USD -13.4299 (forecast USD -0.3655)

Celcuity director Richard E. Buller sells 9,000 shares of company stock

Mirum Pharmaceuticals Reports 43% Increase in Net Product Sales in Q1 and Raises Full-Year Sales Guidance

Amesite

InMed Pharmaceuticals

Meiwu Tech

Co-Diagnostics

Phoenix Asia

Generation Income Properties

MetaVia

Rubico

Virax Biolabs

Agilysys

Pinned News

置顶新闻

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

LABU

SBIO

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

Market Beat

West Pharmaceutical

iShares US Medical Devices

SPDR S&P Health Equip

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Arcadian Asset

S&P 500

RNXT

ARKG

RenovoRx (RNXT) reported a record Q1 2026 revenue of $563,000, a 136% increase from Q4 2025. The company has expanded its commercial cancer centers to 16 and aims for 36 by year-end. Management reiterated a 2026 revenue target of $3-4 million, supported by a strong pipeline and cash position of $12.4 million. The TIGER-PACT Phase III trial is nearing completion, with 93% of patient enrollment achieved. Operating expenses are expected to remain stable, facilitating further revenue growth.

Motley Fool

RenovoRx

iShares Global Healthcare

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares US Pharma

VG Health

RenovoRx (RNXT) Q1 2026 Earnings Transcript

DoctorDerm has announced a comprehensive rebrand and the expansion of its telehealth dermatology platform, introducing new prescription treatments. The rebrand emphasizes simplicity and personalized care, moving away from one-size-fits-all solutions. New offerings include the Copper Peptide Skin Complex for skin quality and the Lash Growth Serum for enhancing lash appearance. Both treatments are available nationwide after evaluation by licensed providers, reflecting DoctorDerm's commitment to accessible, clinically guided skincare.

MorningStar

DoctorDerm Unveils Rebrand and Expands Platform with New Prescription Skin and Lash Treatments

DYAI

IBBQ

Dyadic International will present at Sidoti’s Virtual Investor Conference on May 20, 2026, at 10:00 a.m. ET, and will hold virtual one-on-one investor meetings during the conference window from May 20-21, 2026.

PUBT

Dyadic

Invesco Nasdaq Biotechnology ETF

Dyadic COO Hazelton presents at Sidoti Virtual Investor Conference

Nexalin Technology Inc. (NXL) has acquired PONM Inc. from GreenLight Ventures for $1.3 million, enhancing its HALO Clarity program with AI-integrated remote patient monitoring and virtual clinic management tools. This acquisition supports Nexalin's pivotal trial for moderate-to-severe insomnia, expected to begin in Q2 2026. GreenLight Ventures becomes a significant equity holder and strategic partner, aiding in product and regulatory support. Nexalin's stock closed at $0.32, down 5.26%.

nasdaq

Nexalin Tech

Nasdaq

NEXALIN TECHNOLOGY INC C/WTS 22/09/25(TO PUR COM)

Nexalin Acquires AI Health Platform Ahead Of HALO Clarity Pivotal Trial

GOVX

GeoVax Labs (NASDAQ:GOVX) stock is down 13.57% in premarket trading after an 80% rally, following the announcement of a $3M private placement, raising concerns over shareholder dilution. The offering includes approximately 2.03 million shares and warrants for an additional 4.05 million shares. Despite the drop, the stock remains above its 20-day and 50-day SMAs, but is significantly below its 100-day and 200-day SMAs, indicating a long-term downtrend.

benzinga_article

GeoVax Labs

Direxion S&P Biotech Bear 3X

Shutterstock

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

Why Is GeoVax Labs Stock Falling Tuesday?

TILE

MIRM

OKLO

TYRA

Top Wall Street analysts have initiated coverage on several companies with varying ratings. Oklo Inc (OKLO) received a Peer Perform rating, X-Energy Inc (XE) an Overweight rating with a $41 price target, Mirum Pharmaceuticals Inc (MIRM) an Outperform rating with a $145 target, Interface Inc (TILE) a Buy rating with a $36 target, and Tyra Biosciences Inc (TYRA) a Peer Perform rating.

Interface

Mirum Pharmaceuticals

X-Energy

Oklo

Tyra Biosciences

This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

EDSA

Edesa Biotech will present new clinical data on paridiprubart for acute kidney injury at the 63rd European Renal Association Congress in Glasgow from June 3-6, 2026. The analysis indicates a significant reduction in mortality among patients with acute kidney injury, suggesting a potential targeted therapy. An oral presentation is scheduled for June 5, 2026.

Edesa Biotech

Edesa Biotech presents new paridiprubart acute kidney injury data at ERA Congress

513060

On May 19, 2026, the leading sector was the Energy Select Sector SPDR ETF (XLE) with a price change of +0.22%. The Health Care Select Sector SPDR ETF (XLV) also gained slightly. Conversely, the Technology Select Sector SPDR ETF (XLK) led the losses with a decline of -1.95%, followed by the Industrial (XLI) and Consumer Discretionary (XLY) sectors. This data helps traders analyze market trends for better investment decisions.

Bosera Hang Seng Health Care ETF(QDII)

United States Oil Fund LP

Spdr Select Indu

ProShares Ultra Energy

SPDR S&P Software

iShares US Oil Equip & Svcs

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

SPDR Energy Select

Pro Ultr Bloomberg Crude Oil

SPDR O&G Ex & Prd

VG Energy

ISHRS S&P Glb Engy

iShares Expanded Tech Software Sector ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

VanEck Oil Services ETF

Spdr Select Tech

SPDR FD Consumer Discretionary

Spdr Material

Real Est Select Spdr

Comm Servcies Select Sector SPDR

Financial Select Sector SPDR Fund

SPDR FD Consumer Staples

Leading And Lagging Sectors For May 19, 2026

PACB

Pacific Biosciences has partnered with Blank Bio to produce long-read bulk RNA-seq data for precision oncology. The collaboration aims to utilize PacBio HiFi long-read sequencing on up to 100 fresh frozen tumor samples to enhance tumor stratification, biomarker discovery, and clinical trial design.

Pacific Biosc California

PacBio collaborates with Blank Bio on long-read bulk RNA-seq for oncology models

159849

The Purina Institute is advancing microbiome science in veterinary medicine, focusing on the gut-brain axis and antimicrobial stewardship. Their Microbiome Forum highlighted how gut health influences neurological conditions in pets and emphasized the need for responsible antimicrobial use to protect long-term health. By translating complex research into practical insights, the Institute aims to empower veterinarians to enhance pet health through informed dietary and treatment strategies.

prnewswire

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Proshares UltraShort Nasdaq Biotech

Minsheng Royal CSI Biotechnology Theme ETF

08:59 ETPurina Institute Drives the Conversation on Microbiome Innovation in Veterinary Medicine

REGN

Yesterday, Regeneron Pharma's stock price plummeted 9.82% to $629.68, with a large bearish candlestick engulfing the gains of the previous days. The 5-day and 10-day moving averages were decisively breached, severely damaging the short-term bullish arrangement. The MACD daily line issued a bearish signal below the zero axis, indicating that selling pressure has shifted from testing to active attack, with the short-term trend rapidly weakening. The trading volume reached $1.87 billion, far exceeding the recent average level, showing clear signs of panic selling, with bears completely in control

Technical Forecast

Regeneron Pharma

Pre-market trend | Regeneron Pharma (REGN) plummeted nearly 10% on May 18, is short interest accelerating?

ALPS Medical Breakthrough(SBIO.US)